4.8 Article

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Journal

CANCER CELL
Volume 34, Issue 5, Pages 807-+

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2018.10.001

Keywords

-

Funding

  1. National Cancer Institute (NCI) [CA199235, CA203657]
  2. NCI [T32CA009156, CA42978, CA196510, T32CA071341, F31CA216965]
  3. Pancreatic Cancer Action Network/AACR
  4. Lustgarten Pancreatic Cancer Foundation
  5. American Cancer Society [128014-PF-15-059-01-TBE]
  6. Slomo and Cindy Silvian Foundation
  7. Cancer Center Core Support Grant [P30 CA016086]
  8. Department of Defense

Ask authors/readers for more resources

Our recent ERK1/2 inhibitor analyses in pancreatic ductal adenocarcinoma (PDAC) indicated ERK1/2-independent mechanisms maintaining MYC protein stability. To identify these mechanisms, we determined the signaling networks by which mutant KRAS regulates MYC. Acute KRAS suppression caused rapid proteasome-dependent loss of MYC protein, through both ERK1/2-dependent and -independent mechanisms. Surprisingly, MYC degradation was independent of PI3K-AKT-GSK36 signaling and the E3 ligase FBWX7. We then established and applied a high-throughput screen for MYC protein degradation and performed a kinome-wide proteomics screen. We identified an ERK1/2-inhibition-induced feedforward mechanism dependent on EGFR and SRC, leading to ERK5 activation and phosphorylation of MYC at S62, preventing degradation. Concurrent inhibition of ERK1/2 and ERK5 disrupted this mechanism, synergistically causing loss of MYC and suppressing PDAC growth.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available